GleamWall
中文EN

PMCB PharmaCyte Biotech, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1157075 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,334.7%
TTM EPS YoY-3,566.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.4%
ROA-39.5%
ROIC (approx.)-27.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.8%
Debt / equity0.00x
Current ratio40.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-07-312026Q4*2026-04-302026Q32026-01-312026Q22025-10-312026Q12025-07-312025Q4*2025-04-302025Q32025-01-312025Q22024-10-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$60,000$61,946$93,113$141,085$95,157$126,734$118,196$97,470
SG&A expense$946,708$899,882$2.02M$1.23M$753,148$3.45M$842,056$1.01M
Operating income-$1.01M-$2.51M-$2.12M-$1.38M-$848,305-$1.04M-$960,252-$1.11M
Income tax$0———$0———
Net income-$5.08M-$4.39M$746,860-$7.42M-$8.36M$11.75M-$3.05M-$1.47M
EPS (basic)-0.54—-0.17-1.24-1.23—-0.44-0.39
EPS (diluted)-0.54—-0.17-1.24-1.23—-0.44-0.39
Weighted avg. shares (diluted)10.74M—9.26M6.80M6.80M—6.96M7.64M
Balance sheet
Cash & equivalents$17.74M$18.60M$20.17M$15.41M$13.18M$15.17M$16.38M$20.84M
Short-term investments$99,462$254,010$372,251$201,190$261,853$366,316$372,632—
Current assets$30.97M$37.42M$20.70M$23.02M$19.11M$22.38M$16.96M$21.33M
Intangibles—$0$1.55M$1.55M$1.55M$1.55M$1.55M$1.55M
Total assets$36.71M$46.75M$55.87M$55.98M$45.11M$55.17M$43.83M$55.10M
Current liabilities$768,682$826,424$1.68M$1.58M$1.06M$2.91M$1.19M$4.78M
Total liabilities$6.90M$11.77M$16.47M$19.42M$1.52M$3.28M$3.58M$11.65M
Shareholders' equity$27.51M$33.29M$38.11M$35.24M$43.59M$51.89M$40.25M$43.45M
Shares outstanding10.74M10.74M10.74M—6.80M6.80M6.90M7.03M
Cash flow statement
Operating cash flow-$780,894-$1.39M-$786,848-$979,523-$1.99M-$1.04M-$509,893-$1.05M
Investing cash flow—$0$5.00M-$3.00M$0$0$0$0
Financing cash flow-$83,399-$169,818$543,779$6.21M$0-$171,543-$3.95M-$10.74M
Stock-based compensation—$0$771,516$60,492$60,492$0$72,861$119,155
Share buybacks—$0$401,625$0$0$171,543$225,025$1.40M

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.